RG6434
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 03, 2026
Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease
(CTAD 2026)
- No abstract available
Clinical • P2 data • Alzheimer's Disease • CNS Disorders • NLRP3
August 03, 2026
The NLRP3 inflammasome as a therapeutic target in Alzheimer's disease: biomarker, preclinical evidence and Phase I healthy participants' safety data of the oral inhibitor RG6434
(CTAD 2026)
- No abstract available
P1 data • Preclinical • Alzheimer's Disease • CNS Disorders • NLRP3
1 to 2
Of
2
Go to page
1